MarketCap
Facebook
X
Telegram
SELLAS Life Sciences Group Net Debt | SLS
Net Debt can be roughly defined as financial liabilities that an entity classifies in the financing section together with the resources available to service those financial liabilities[1]
Net debt is the obligations that remain after deducting all assets and other liabilities from a company or individual. It represents the sum of debts that an organization or person must repay to their creditors or other parties.
Net debt can include various types of obligations such as loans, borrowings, lease liabilities, or credit card payments. It is important to note that net debt does not include current expenses or obligations such as payroll expenses or current bills.
Assessing net debt is an important financial indicator for evaluating the financial position of a company or individual. If net debt significantly exceeds assets, it may indicate financial difficulties and insolvency. In such cases, the company or individual may face difficulties in meeting their obligations and managing their finances.
Net debt can also be used to compare the financial stability of different companies. The lower the net debt relative to assets, the more stable and financially sound they are considered.
Overall, understanding net debt helps evaluate the financial soundness and ability of a company to meet their obligations. It is an important indicator that assists in making decisions about lending, investments, and financial management.
Annual Net Debt SELLAS Life Sciences Group
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -70.8 M | -12.9 M | -1.62 M | -16.2 M | -20.5 M | -33.7 M | -7.06 M | -5.34 M | 8.67 M | -1.69 M | -25 M | -15.2 M | -37.9 M | -32.8 M | -10.9 M | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 8.67 M | -70.8 M | -18.9 M |
References
- Pizzo, M., Moscariello, N., & Vinciguerra, R. (2015). Market Incentives and Regulators' Activity Shaping Financial Information: An Analysis of the Net Debt Disclosure in Italy. International Journal of Business and Management, 10(1), 1.
Net Debt of other stocks in the Biotechnology industry
| Issuer | Net Debt | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Celsion Corporation
CLSN
|
-7.77 M | - | -6.63 % | $ 13.9 M |  USA |
 |
FSD Pharma
HUGE
|
-16.8 M | - | 5743.5 % | $ 69.7 M |  Canada |
 |
Qilian International Holding Group Limited
QLI
|
-9.5 M | - | -6.08 % | $ 184 M |  China |
 |
Happiness Biotech Group Limited
HAPP
|
-7.39 M | - | 1.35 % | $ 17.8 M | China |
 |
Synthetic Biologics
SYN
|
-10.8 M | - | 1.32 % | $ 16.2 M | USA |
 |
Dynavax Technologies Corporation
DVAX
|
-65.3 M | - | - | $ 2.02 B | USA |
 |
BioXcel Therapeutics
BTAI
|
56.3 M | $ 1.19 | 5.31 % | $ 14.5 M | USA |
 |
Burford Capital Limited
BUR
|
1.56 B | $ 4.37 | 0.23 % | $ 958 M |  Britain |
 |
I-Mab
IMAB
|
-2.1 B | - | - | $ 866 M | China |
 |
BeyondSpring
BYSI
|
-2.33 M | $ 0.84 | 34.27 % | $ 34.5 M | USA |
 |
AgeX Therapeutics
AGE
|
71 K | - | -10.17 % | $ 12.2 K | USA |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
-402 M | - | - | $ 40.3 B | USA |
 |
Genfit SA
GNFT
|
2.27 M | - | 2.54 % | $ 160 B |  France |
 |
Biophytis SA
BPTS
|
-4.01 M | - | -13.47 % | $ 169 M | France |
 |
Cerus Corporation
CERS
|
-6.9 M | $ 2.98 | 4.93 % | $ 568 M | USA |
 |
Compugen Ltd.
CGEN
|
-87.6 M | $ 2.41 | 4.17 % | $ 225 M |  Israel |
 |
CureVac N.V.
CVAC
|
-443 M | - | - | $ 867 M |  Germany |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
-824 K | - | -1.52 % | $ 24.7 M | USA |
 |
Athira Pharma
ATHA
|
-68.5 M | - | - | $ 269 M | USA |
 |
BiondVax Pharmaceuticals Ltd.
BVXV
|
52 M | - | 0.74 % | $ 768 M | Israel |
 |
Abcam plc
ABCM
|
15.3 M | - | - | $ 4.9 B | Britain |
 |
Завод ДИОД
DIOD
|
-48.6 M | - | - | - |  Russia |
|
Galera Therapeutics
GRTX
|
-17 M | - | -32.59 % | $ 7.61 M | USA |
 |
Midatech Pharma plc
MTP
|
-6.17 M | - | -18.52 % | $ 27.3 M | Britain |
 |
Hepion Pharmaceuticals
HEPA
|
-14.6 M | - | -18.79 % | $ 39.3 K | USA |
 |
ARCA biopharma
ABIO
|
-45 M | - | 1052.0 % | $ 415 M | USA |
 |
MorphoSys AG
MOR
|
-146 M | - | 2.43 % | $ 254 M | Germany |
|
Champions Oncology
CSBR
|
-3.34 M | $ 5.1 | 2.63 % | $ 70.5 M | USA |
 |
Affimed N.V.
AFMD
|
-31.3 M | - | -34.95 % | $ 21.5 M | Germany |
 |
AnPac Bio-Medical Science Co., Ltd.
ANPC
|
5.43 M | - | -1.58 % | $ 28.1 M | China |
 |
Celyad Oncology SA
CYAD
|
-12.2 M | - | - | $ 12.5 M |  Belgium |
 |
Adial Pharmaceuticals
ADIL
|
-3.85 M | $ 3.98 | 1.86 % | $ 2.66 M | USA |
 |
Generation Bio Co.
GBIO
|
17.3 M | - | - | $ 344 M | USA |
 |
Akero Therapeutics
AKRO
|
-340 M | - | - | $ 3.67 B | USA |
 |
AnaptysBio
ANAB
|
-224 M | $ 58.47 | 4.37 % | $ 1.68 B | USA |
 |
Anika Therapeutics
ANIK
|
-31.2 M | $ 21.5 | 1.56 % | $ 308 M | USA |
 |
Cyclacel Pharmaceuticals
CYCCP
|
-3.5 M | - | -4.36 % | $ 27 M | USA |
 |
Gracell Biotechnologies
GRCL
|
-1.39 B | - | - | $ 3.37 B | China |
 |
Aurinia Pharmaceuticals
AUPH
|
-26.8 M | $ 15.47 | 1.91 % | $ 2.08 B | Canada |
 |
GlycoMimetics
GLYC
|
-212 M | - | 9357.83 % | $ 1.01 B | USA |
 |
Aeterna Zentaris
AEZS
|
-5.16 M | - | 5.93 % | $ 314 M | Canada |
 |
AVROBIO
AVRO
|
-253 M | - | 1083.1 % | $ 745 M | USA |
 |
BeiGene, Ltd.
BGNE
|
-3.56 B | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
Bicycle Therapeutics plc
BCYC
|
-625 M | $ 3.9 | 0.24 % | $ 270 M | Britain |
 |
Beam Therapeutics
BEAM
|
-141 M | $ 26.75 | 0.91 % | $ 2.65 B | USA |
 |
AIkido Pharma
AIKI
|
-31.2 M | - | 1.93 % | $ 17.4 M | USA |
 |
Aeglea BioTherapeutics
AGLE
|
-30.2 M | - | - | $ 1.01 B | USA |
 |
BioMarin Pharmaceutical
BMRN
|
-1.3 B | $ 67.36 | 0.99 % | $ 12.9 B | USA |
 |
Aptose Biosciences
APTO
|
-5.53 M | - | -45.71 % | $ 1.2 M | Canada |